OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patients Approval supported by data from the Phase 3 KEYNOTE-B96 trial in which the ...

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Keytruda and Padcev combination improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905 trial showed significant event-free survival ...

Keytruda and Padcev combination shows improved event-free and overall survival in muscle invasive bladder cancer patients ineligible for cisplatin. The KEYNOTE-905/EV-303 trial demonstrated ...

The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...